Type 2 Diabetes Mellitus, Osteoporosis
Conditions
Interventions
Calcium / Vitamin D / Magnesium mixed tablet
Calcium 305mg, Cholecalciferol 0.005mg (200IU), Magnesium carbonate 59.2mg is containing per tablet. Taking 2 tablet / day prior 1 month from Denosumab 60mg injection to subcutaneous, once per 6 month
Sponsors
Tokyo Women's Mediclcal University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient of type 2 Diabetes Mellitus 1: More than 50 years of age at the time of obtaining informed consent 2:With osteoporosis 3: At the participation in this study, that document consent is obtained due to free will of the patient's own by sufficient explanation and thorough understanding. 4:Control of blood pressure and blood glucose are relatively stable, and without planning for remarkable change.
Exclusion criteria
Exclusion criteria: The patients who Taking drug for osteoporosis With presence and past history of malignancy. With other endocrine diseases With liver dysfunction except fatty liver With macro proteinuria or with increased serum creatinine level over 2.0mg/dl Principal investigator of this study has determined to be inappropriate as a subject
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of the Basal metabolism, and the marker of the bone metabolism before and after taking Calcium/Vitamin D and denosumab | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of the blood glucose control level, fasting CPR, iPTH, 25hydroxyvitamin D, blood cell count, serum calcium, phosphate and other general examination of blood, and diabetic neuropathy | — |
Countries
Japan
Contacts
Public ContactMakiko Ogata
Tokyo Women's Medical University Diabetes Center
Outcome results
None listed